Close Menu

NEW YORK (360Dx) – Specific Diagnostics announced today that CARB-X has awarded $1.7 million in second-stage funding for development of its Reveal rapid antibiotic susceptibility test (AST) instrument, based on the firm achieving development and testing milestones.

Mountain View, California-based Specific Diagnostics said that the additional funding will enable its preparation for clinical trials this year. It is readying the system for regulatory validation to enable its launch and use in hospitals.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.